Kevzara (sarilumab) works by blocking a specific protein receptor in the body that drives inflammation. It targets the interleukin-6 (IL-6) receptor, a key player in the inflammatory chain reaction behind rheumatoid arthritis and other conditions. By attaching to this receptor before IL-6 can, Kevzara effectively shuts down one of the body’s most potent inflammatory signals at its source.
How IL-6 Drives Inflammation
IL-6 is a signaling molecule your immune system uses to coordinate inflammation. In healthy people, it plays a useful role in fighting infections and healing injuries. But in conditions like rheumatoid arthritis, the body produces far too much IL-6, and it keeps the immune system in a constant state of attack. This sustained inflammation is what causes joint swelling, pain, stiffness, and over time, permanent damage to cartilage and bone.
IL-6 does its work by docking onto IL-6 receptors, which exist in two forms: ones anchored to the surface of cells and ones floating freely in the bloodstream. Both forms can trigger inflammatory signaling. This is important because some inflammatory pathways only need the free-floating version to activate, meaning the inflammation can spread to tissues that don’t even carry the receptor on their surface.
Kevzara’s Blocking Mechanism
Kevzara is a monoclonal antibody, a lab-made protein designed to bind to one very specific target. It attaches to both the cell-surface and free-floating forms of the IL-6 receptor with high affinity, physically preventing IL-6 from connecting. Without that connection, the downstream signaling cascade never fires, and the inflammatory response quiets down.
This dual blocking action is what sets IL-6 receptor inhibitors apart from treatments that target other parts of the immune system. Rather than broadly suppressing immune activity, Kevzara interrupts a specific signaling pathway that is overactive in rheumatoid arthritis. The result is a meaningful reduction in systemic inflammation, which shows up clearly in blood work: C-reactive protein (CRP), a standard marker of inflammation, typically drops into the normal range within weeks of starting treatment.
How It Compares to Other IL-6 Inhibitors
Kevzara is not the only medication that blocks the IL-6 receptor. Tocilizumab (Actemra) targets the same receptor but differs in its binding characteristics. Sarilumab has a higher binding affinity for the IL-6 receptor, meaning it latches on more tightly. Research published in Clinical and Experimental Rheumatology found that when both drugs are given at their standard every-two-week subcutaneous doses, sarilumab occupies a significantly higher percentage of IL-6 receptors than tocilizumab. However, tocilizumab given weekly (its alternative dosing schedule) achieves higher receptor occupancy than sarilumab given every two weeks.
In practical terms, both drugs are effective IL-6 blockers. The clinical differences between them are modest, and choosing one over the other typically comes down to individual response, side effect profiles, and insurance coverage rather than a clear superiority of one mechanism.
What the Clinical Results Look Like
The effectiveness of Kevzara has been measured using ACR response scores, a standardized way of grading improvement in rheumatoid arthritis symptoms. An ACR20 score means at least 20% improvement in joint tenderness, swelling, and other measures. ACR50 and ACR70 represent progressively higher bars.
In two major clinical trials, patients taking the 200 mg dose alongside methotrexate hit these benchmarks at notably higher rates than those on methotrexate alone. At 24 weeks, roughly 61 to 66% of patients on sarilumab achieved ACR20, compared to about 33% on placebo. Nearly half (41 to 46%) reached ACR50, meaning their symptoms were cut in half or more. And about 16 to 25% hit ACR70, representing a dramatic improvement. The 150 mg dose also outperformed placebo, though the 200 mg dose consistently performed better across trials.
Beyond symptom relief, Kevzara rapidly brings down CRP levels. In clinical studies, CRP dropped into the normal range (below 10 mg/L) within the first few months of treatment, and about two-thirds of patients on the 200 mg dose maintained that reduction through a full year.
How It’s Taken
Kevzara is a subcutaneous injection, meaning it goes just under the skin rather than into a vein. The standard dose is 200 mg every two weeks, delivered through a prefilled syringe or pen that patients use at home. It can be taken on its own or alongside methotrexate or other conventional disease-modifying drugs.
If blood tests show certain side effects like a drop in white blood cells, low platelets, or elevated liver enzymes, the dose may be reduced to 150 mg every two weeks. In some cases, treatment is paused temporarily until lab values stabilize.
Side Effects and Risks
Because Kevzara dials down part of the immune system’s inflammatory response, it also reduces some of the body’s infection-fighting capacity. The FDA’s boxed warning highlights an increased risk of serious infections, including tuberculosis, invasive fungal infections, and bacterial or viral infections caused by opportunistic pathogens. Patients are tested for latent tuberculosis before starting the drug, and anyone with latent TB receives treatment for it before beginning Kevzara.
The most common lab abnormality is a drop in neutrophils, a type of white blood cell that fights bacterial infections. This is a direct consequence of blocking IL-6 signaling, since IL-6 normally stimulates neutrophil production. Elevated liver enzymes and changes in cholesterol levels also occur frequently enough that regular blood monitoring is part of the treatment plan. Most patients have blood drawn before starting, then periodically in the first months to watch for these shifts.
Injection site reactions (redness, itching, or mild pain at the injection spot) are among the more common day-to-day side effects but tend to be mild and short-lived. The risk of serious side effects is highest in patients already taking other immunosuppressants like corticosteroids or methotrexate alongside Kevzara, since the combined effect on the immune system is greater.
What Kevzara Is Approved to Treat
Kevzara was originally approved by the FDA in 2017 for moderate-to-severe rheumatoid arthritis in adults who had an inadequate response to one or more other disease-modifying drugs. It has since gained approval for polymyalgia rheumatica (PMR), a condition that causes widespread muscle pain and stiffness, particularly in the shoulders and hips, and is also driven by IL-6-mediated inflammation. In PMR, Kevzara helps patients taper off corticosteroids, which are the standard treatment but carry significant long-term side effects. In the PMR trial, about 67% of patients on sarilumab maintained low CRP levels from week 12 through week 52, compared to 45% of those on a longer steroid taper alone.